Lucentis: payments to doctors
Payments that named Lucentis as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $14.6M
- Providers
- 2,616
- Transactions
- 11,450
- Average per transaction
- $1,277
The per-transaction average — $1,277 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 2,616 providers the average total is $5,589, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Genentech, Inc. | $10,386,291 | 71.0% |
| Genentech USA, Inc. | $3,874,996 | 26.5% |
| F. Hoffmann-la Roche AG | $358,165 | 2.4% |
| Novartis | $124 | 0.0% |